SCHEMBL9703943

SCHEMBL9703943

CCn1c(=O)c(C(=O)O)nc2ccc([N+](=O)[O-])cc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.52
CFTR P13569 1/20 0.51
MAPK1 P28482 1/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
MAPT P10636 3/20 0.48
ALDH1A1 P00352 3/20 0.48
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
NPBWR1 P48145 1/20 0.48
MCHR1 Q99705 1/20 0.48
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
LMNA P02545 3/20 0.47
POLB P06746 2/20 0.47
AHR P35869 1/20 0.47
CASP6 P55212 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KDR P35968 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9704330 0.82 MAPK1 (0.45) CFTRMAPK1CASP1CASP7MAPT
SCHEMBL7261471 0.79 CYP1A2 (0.56) CYP1A2CFTRMAPTALDH1A1RAB9A
SCHEMBL9703964 0.75 MAPK1 (0.58) CYP1A2MAPK1CASP1CASP7MAPT
SCHEMBL9704918 0.74 MAPK1 (0.50) CYP1A2MAPK1CASP1CASP7MAPT
SCHEMBL10466284 0.74 CYP1A2 (0.48) CYP1A2CFTRMAPTALDH1A1RAB9A
SCHEMBL9703578 0.73 MAPK1 (0.49) CYP1A2MAPK1CASP1CASP7MAPT
SCHEMBL9705722 0.73 MAPK1 (0.49) CYP1A2MAPK1CASP1CASP7MAPT
SCHEMBL3964662 0.72 MEN1 (0.53) CYP1A2MAPTALDH1A1RAB9ANPC1
SCHEMBL6606816 0.72 NLRP3 (0.59) CYP1A2MAPK1CASP1CASP7MAPT
SCHEMBL6275418 0.72 RAB9A (0.47) CYP1A2MAPTALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1992011245-A1 2-ACYLAMIDO DERIVATIVES OF 3,4-DIHYDRO-3-OXO-QUINOXALINE HAVING PHARMACEUTICAL ACTIVITY WARNER-LAMBERT COMPANY (US) 1992-07-09 WO disclosed